Rigor Reviewed

Rigor-Reviewed Manuscript

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

Name: Αlpha¹ Rigor Record — Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Item: Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.
Rating: 59
Author: Αlpha¹

Wainberg ZA, Manji GA, Bahary N, Ulahannan SV, Pant S, Spigel DR, Uboha NV, Oberstein PE, Saeed A, Beagle B, Kim JY, Wang N, Weeder B, Shitole S, Mrouj K, Scott JR, Ensign LG, DiRenzo DM, Walters MJ, Wu W, Kaplan A, Cho S, Kabbarah O, O'Reilly EM

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 8 high issues for “Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 10, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×3−1.5★
ReportingKey resources partially met−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: moderateReviewer agreement: moderateEngine: 7.29.0Source: full text

Not verified in this report

References were not verified against Crossref/OpenAlex.
The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run on this paper: the pass that reads its reported means did not complete. No reported mean was checked for arithmetic impossibility.

Problems surfaced5 types

Numerical inconsistencies1

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

Data authenticity concerns1

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

Reporting gaps2

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed
Key resources under-identified (antibodies, cell lines, RRIDs)Assessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

The manuscript is a well-designed and transparently reported phase 1b exploratory trial with a strong scientific rationale, sound ethics documentation, and careful, estimation-framed statistical reporting; the 10 machine-recomputed tests were all consistent. Its main weaknesses are in resource authentication (unidentified mIF/ISH antibodies and probes, no cell-line STR authentication or mycoplasma testing) and data/code availability (no sequencing accession numbers, no shared analysis code), plus minor reporting gaps (no CONSORT reference, disclosed-but-unreported secondary endpoints, and a low-severity percentage rounding inconsistency).

Three independent reviewer runs (same model) were synthesized; reviewers converged on six dimensions and diverged on study design (1 warn vs 2 pass) and data code availability (1 fail vs 2 warn), both resolved to the majority with reasoning preserved. Statistics verification recomputed only 10 of the reported tests (those with a statistic + df or effect + CI); threshold-only, q-value, and resampling/exact p-values were not machine-verified and are not endorsed. Citation check was not run (0 references checked). All 5 data/code links verified live; no retracted or not-found references were flagged.

12 major claims checked against the paper's own evidence: all adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 10 tests: 10 consistent, 0 inconsistent; 7 recomputed directly from the reported test statistics, 3 via agent-written checks.

3 integrity concerns flagged (0 high).

Reporting

Eight Dimensions6 pass · 2 warn

The introduction extensively cites prior research on CD73 and adenosine in cancer, the rationale for targeting CD73 in PDAC, and the limitations of existing adenosine signatures. The hypothesis that CD73 inhibition may benefit patients with mPDAC is logically derived from the cited evidence. The paper acknowledges that previous transcriptional signatures had limited predictive value, and proposes NR4A family expression as a novel surrogate, thereby addressing gaps in prior research.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (3) — the votes behind the verdict

PASSReviewer 1· 95% conf

The paper establishes a strong scientific foundation by citing prior work on CD73, adenosine, and PDAC, providing a logical rationale for the study, and addressing limitations of previous transcriptional signatures.

Evidence

paraphrase[Introduction, paragraph 1]

“The ectonucleotidase CD73 is a key enzyme involved in the production of extracellular adenosine from adenosine triphosphate (ATP).”

direct quote[Introduction, paragraph 3]

“However, these transcriptional signatures have limited predictive value, in part because they may not adequately reflect the cellular heterogeneity in the TME.”